Outcomes following ICI with single-agent anti–PD-1 were comparable or superior to other adult hypermutated cancers (8–13, 14), with the first-ever objective responses in refractory glioblastoma, translating to a remarkable 3-year overall survival of 39% for tumors failing chemoradiation (16). This evidence concerns the gene PDCD1 and glioblastoma.